Abstract
Neuroimaging studies in substance use disorder have shown widespread impairments in white matter (WM) microstructure suggesting demyelination and axonal damage. However, substantially fewer studies explored generalized vs. acute/specific drug effects on WM. Our study assessed whole-brain WM integrity in three subgroups of addicted individuals, encompassing cocaine (CUD) and heroin (HUD) use disorder, compared to healthy controls (CTL).
Diffusion MRI was acquired in 58 CTL, 28 current cocaine users/CUD+, 32 abstinent cocaine users/CUD−, and 30 individuals with HUD (positive urine for cocaine in CUD+ and opiates used for treatment in HUD). Tract-Based Spatial Statistics allowed voxelwise analyses of diffusion metrics [fractional anisotropy/FA, mean diffusivity/MD, radial diffusivity/RD, and axial diffusivity/AD]. Permutation statistics (p-corrected<.05) were used for between-group t-tests.
Compared to CTL, all drug-addicted individuals showed widespread FA reductions, and increased MD, RD, and AD (19-57% of WM skeleton, p<.05). The HUD showed the most impairments, followed by the CUD+, with only minor FA reductions in CUD− (<.2% of skeleton, p=.05). Longer periods of regular use were associated with decreased FA and AD, and higher subjective craving was associated with increased MD, RD, and AD, across all drug-addicted individuals (p<.05).
These findings demonstrate extensive WM impairments in drug-addicted individuals characterized by decreased anisotropy and increased diffusivity, thought to reflect demyelination and lower axonal packing. Extensive abnormalities in both groups with positive urine status (CUD+ and HUD), and correlations with craving, suggest greater WM impairments with recency of use. Results in CUD−, and correlations with regular use, further imply cumulative and/or persistent WM damage.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute on Drug Abuse (Goldstein, 1R01DA048301-01A1), the National Center for Complementary and Integrative Health (Goldstein, 1R01AT010627-01), and the Canadian Institutes of Health Research (Gaudreault, postdoctoral research fellowship).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent and study procedures were approved by the Icahn School of Medicine at Mount Sinai institutional review board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
